Ligand Pharmaceuticals Reports Strong Q3 2026 Results and Raises Full-Year EPS Guidance
Ligand Pharmaceuticals (LGND) reported significant growth in its third quarter of 2026, driven largely by the strategic acquisition of XOMA. Total royalty revenue reached $70.3 million, a 51% increase year-over-year, bolstered by commercial momentum from Filspari and Ohtuvayre alongside new contributions from XOMA assets. While core revenue saw a slight decline due to the absence of one-time out-license income from the previous year, underlying growth remains robust. Following strong performance through the first nine months of the year, management raised its full-year 2026 adjusted EPS guidance to a range of $9.50 to $9.75. The company maintains a strong liquidity position with approximately $750 million in total deployable capital and an expanded financial royalty assets balance of $800 million. Looking ahead, Ligand continues to aggressively pursue investment opportunities, having reviewed 180 deals so far this year.
Tickers: $LGND
Topics: Acquisition EPS Guidance Financial Results Royalty Revenue